GSK and MMV present positive data on treatment for Plasmodium vivax malaria in children

▴ GSK and MMV present positive data on treatment for Plasmodium vivax malaria in children
GSK and MMV today presented positive data from the TEACH study of tafenoquine, an 8-aminoquinoline, for the prevention of relapse of Plasmodium vivax malaria in children and adolescents.

GSK and Medicines for Malaria Venture (MMV) today presented positive data from the TEACH study of tafenoquine, an 8-aminoquinoline, for the prevention of relapse (radical cure) of Plasmodium vivax (P. vivax) malaria in children and adolescents.

The results of the Tafenoquine Exposure Assessment in Children (TEACH) study were presented during the American Society of Tropical Medicine & Hygiene 2020 virtual annual meeting.

TEACH evaluated dosages of tafenoquine based on the weight in children and adolescents between the age of 6 months and up to 15 years. The safety profile was consistent with previous clinical studies with the exception of early post-dose vomiting. Ninety-five percent of the study’s 60 subjects had no recurrence of P. vivax malaria during four months of follow-up.

The current standard of care for prevention of P. vivax relapse requires a 7- or 14-day course of treatment and at present there is no age-specific pediatric formulation. Tafenoquine is a single dose treatment for radical cure and is already licensed in people aged 16 and older. TEACH investigated the use of a novel 50 mg dispersible tablet, which was developed to facilitate use in children. The study also used the approved 150 mg tablet.

Tags : #LatestPharmaNewsNov20 #LatestGskNewsNov20 #TreatmentforMalaria

About the Author


Sana Farid Khan

“The best way to become acquainted with a subject is to write about it."
A confident counselor, a speaker, and an educator, ready to utilize my communication skills effectively in the world of healthcare by putting pen to paper to reach new heights of success.
You can write to me at [email protected]

Related Stories

Loading Please wait...
-Advertisements-


Trending Now

BioNTech and Fosun Pharma announce the start of phase 2 clinical trial of COVID-19 Vaccine in ChinaNovember 25, 2020
1,031 new cases of COVID-19 confirmed in Himachal PradeshNovember 25, 2020
Cooking with wood may cause lung damageNovember 25, 2020
More than 56 lakh sample tests for COVID-19 conducted in OdishaNovember 25, 2020
COVID-19 recovery rate in Bihar improves to 97.30 pctNovember 25, 2020
Green Mediterranean (‘green Med’) diet may be even better for healthNovember 25, 2020
Chhattisgarh: Intensive Covid screening of all passengers to be done mandatorily at airportsNovember 25, 2020
New guidance issued on policies to protect populations in vulnerable situations in context of COVID-19November 25, 2020
Life Extension® Launches Bloat Relief Formula.November 25, 2020
Todos Medical Completes Installation of Lab Automation Equipment at Wisconsin Lab Client to Support COVID-19 PCR TestingNovember 25, 2020
Bristol Myers Squibb Receives European Commission Approval for OpdivoNovember 25, 2020
QualTex Laboratories adds Ortho Diagnostics VITROS® Anti-SARS-CoV-2 IgG assayNovember 25, 2020
China resorts to rigorous measures after multiple locally transmitted coronavirus cases detected in three citiesNovember 25, 2020
National COVID-19 recovery rate reaches 93.72 pctNovember 25, 2020
Nearly 11,60,000 COVID samples tested in country in last 24 hoursNovember 25, 2020
Lokelma label update approved in China for patients with hyperkalaemia on chronic haemodialysisNovember 25, 2020
Taking the Pill may cut risk of severe asthma bouts in women of reproductive ageNovember 25, 2020
Multilateral cooperation is key to overcoming global challenges such as COVID-19: Dr Harsh VardhanNovember 25, 2020
Polaryx Therapeutics receives both rare pediatric disease and orphan drug designations from US FDANovember 25, 2020
Panaxia and Neuraxpharm expand strategic collaboration to France with medical cannabisNovember 25, 2020